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The rise in new psychoactive substances that are available as ‘research 
chemicals’ (RCs) remains a significant forensic and legislative challenge. A 
number of arylcyclohexylamines have attracted attention as RCs and 
continued to be encountered, including 3-MeO-PCP, 3-MeO-PCE and 3-
MeO-PCPr. These compounds are commonly perceived as ketamine-like 
dissociative substances and are believed to act predominantly via 
antagonism of the N-methyl-D-aspartate (NMDA) receptor. To aid in the 
identification of newly emerging substances the syntheses of fifteen N-
alkyl-arylcyclohexylamines are described. Analytical characterizations were 
performed via gas chromatography and high performance liquid 
chromatography coupled to multiple forms of mass spectrometry as well as 
nuclear magnetic resonance spectroscopy, ultraviolet diode array detection 
and infrared spectroscopy. The series consisted of the N-alkyl derivatives 
(N-methyl, N-ethyl, N-propyl) of phenyl-substituted and isomeric 2-, 3- 
and 4-methoxy phenylcyclohexylamines, as well as the N-alkyl derivatives 
obtained from a 3-methylphenyl and 2-thienyl moiety. In addition to the 
presentation of a range of previously unreported data, it was also found 
that positional isomers of aryl methoxyl-substituted arylcyclohexylamines 
were readily distinguishable under a variety of analytical conditions.  
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Abstract 
 
The rise in new psychoactive substances that are available as ‘research chemicals’ 
(RCs) remains a significant forensic and legislative challenge. A number of 
arylcyclohexylamines have attracted attention as RCs and continued to be 
encountered, including 3-MeO-PCP, 3-MeO-PCE and 3-MeO-PCPr. These 
compounds are commonly perceived as ketamine-like dissociative substances and 
are believed to act predominantly via antagonism of the N-methyl-D-aspartate 
(NMDA) receptor. To aid in the identification of newly emerging substances the 
syntheses of fifteen N-alkyl-arylcyclohexylamines are described. Analytical 
characterizations were performed via gas chromatography and high performance 
liquid chromatography coupled to multiple forms of mass spectrometry as well as 
nuclear magnetic resonance spectroscopy, ultraviolet diode array detection and 
infrared spectroscopy. The series consisted of the N-alkyl derivatives (N-methyl, N-
ethyl, N-propyl) of phenyl-substituted and isomeric 2-, 3- and 4-methoxy 
phenylcyclohexylamines, as well as the N-alkyl derivatives obtained from a 3-
methylphenyl and 2-thienyl moiety. In addition to the presentation of a range of 
previously unreported data, it was also found that positional isomers of aryl methoxyl-
substituted arylcyclohexylamines were readily distinguishable under a variety of 
analytical conditions.  
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Introduction 
 
The non-medical use of dissociative drugs including 1-(1-phenylcyclohexyl)piperidine 
(PCP), ketamine and their derivatives is a challenge to policy makers, clinicians and 
forensic investigators charged with their identification. More recent examples of 
dissociative drugs include ‘research chemicals’ (RCs) such as 3-MeO-PCP, 
methoxetamine (MXE), diphenidine and 2-methoxydiphenidine (2-MXP).[1-4] In the UK, 
a range of arylcyclohexylamines were placed under control in 2013 following generic 
legislation[5] but control status varies across the globe. Within one week of 
introducing generic control, diphenidine was available for purchase in the UK, which 
added to the existing product catalogues of substances suspected to show 
dissociative properties in humans.[1] The association of some those newly emerging 
substances with acute toxicity[6-8] serves as a reminder that the accurate identification 
of these substances is essential for the monitoring of new psychoactive 
substances.[9,10]  
 
The major pharmacological mechanism that appears to mediate a significant portion 
of the therapeutically relevant and psychoactive effects of dissociative substances 
includes uncompetitive antagonism of the N-methyl-D-aspartate (NMDA) receptor. 
NMDA receptor antagonists exemplify an important pharmacological class that 
provides promising pharmacological tools. They are used or are being investigated in 
a number of therapeutic areas including general anesthetics, neuroprotection, 
management of neuropathic pain and depression.[1,11,12] Issues linked with clinical 
tolerability remain challenging for clinical development of this promising 
pharmacological class.[1,13,14]  
 
Recently a study of the receptor binding profiles of a series of dissociative legal highs 
included 3-methoxyeticyclidine (3-MeO-PCE) (3b).[15] Consistent with reports of its 
potent dissociative effects in humans[1] it showed high affinity for (+)-[3H]MK-801 
labeled NMDA receptors (61 nM). In addition, affinity for the serotonin transporter 
(115 nM) and lesser affinity at sigma-1 and sigma-2 receptor sites were observed.[15] 
It is unknown how these additional pharmacological interactions may contribute to 
the psychoactive properties of 3-MeO-PCE and related arylcyclohexylamines and 
further studies are warranted to explore polypharmacological mechanisms that may 
be relevant as well.  
 
N-Alkyl-arylcyclohexylamines including PCE, PCPr and PCiP (Figure 1) were sold on 
‘street markets’ during the 1960-1990s in the United States and PCE in particular 
enjoyed a large distribution relative to other PCP derivatives.[1] Furthermore, a 
number of N-alkoxyalkyl secondary amine derivatives were detected in Germany 
during the 1990s and included PCMEA, PCEEA, PCMPA and PCEPA (Figure 1), 
respectively.[16-18] More recently, 3-MeO-PCE (3b)[19] and 3-MeO-PCPr (3c) have 
been sold through Internet based vendors (Figure 1).[1,20] Several closely related 
compounds included derivatives of ketamine, such as methoxetamine, 2-MeO-2-
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 3
deschloroketamine (‘2-MeO-ketamine’, 2-MK) and N-ethylnorketamine (‘N-ethyl-
ketamine’, N-EK) (Figure 1) were previously reported.[1,19,21] The analytical 
characterizations of a series of tertiary amine based arylcyclohexylamines including 
‘research chemicals’ 3-MeO- and 4-MeO-PCP was previously reported.[4] Although a 
previous publication described the appearance of 3-MeO-PCE,[20] detailed 
information on analytical profiles of the secondary amine N-alkyl-
arylcyclohexylamines are lacking.  
 
This study presents the syntheses of 15 N-alkyl-arylcyclohexylamines (1a) – (5c) 
using facile routes that are easily adaptable to forensic laboratories. The series 
included the N-alkyl derivatives (N-methyl, N-ethyl, N-propyl) of 2-, 3- and 4-MeO- 
arylcyclohexylamine isomers as well as 3-methylphenyl and 2-thienyl compounds 
(Figure 2A). The comprehensive analytical characterizations included the 
differentiation between positional isomers of aryl methoxyl-substituted 
arylcyclohexylamines.  
 
 
Experimental 
 
Materials 
 
All starting materials, reagents and solvents used for synthesis (≥ 96%) were 
obtained from Sigma-Aldrich (St. Louis, USA). Column chromatography was 
conducted using Merck silica gel, grade 9385 (230-400 mesh, 60 Å). Melting point 
ranges were obtained using a DigiMelt A160 SRS melting point apparatus (Stanford 
Research Systems, Sunnyvale, USA) at a ramp rate of 2 °C/min.  
 
Synthesis procedures 
A representative example is shown for the preparations of (1a) – (1c), where the 
appropriately substituted Grignard reagent served as the starting point (Figure 2B). 
NMR data for compounds (1a) – (5c) are provided in Tables 1–6. NMR data of the 
primary amines are shown as supplementary information.   
 
Preparation of 1-(thiophen-2-yl)cyclohexan-1-amine (TCA)  
 
A solution containing the desired Grignard reagent was prepared consisting of 2-
bromothiophene (147 mmol, 24.08 g) in 200 mL dry THF containing freshly crushed 
Mg (442 mmol, 10.75 g) at room temperature under argon. After stirring for 12 hours 
at room temperature, cyclohexanone (114 mmol, 11.14 g) was added slowly. The 
exothermic reaction mixture was then stirred for an additional 24 hours at which point 
it was quenched with 300 mL distilled water (dH2O), titrated to pH 7 with a saturated 
NH4Cl solution and extracted with ethyl acetate (3 x 100 mL). Organic phases were 
pooled, washed with a saturated sodium bisulfite solution (2 x 150 mL), saline (1 x 
150 mL), dried with anhydrous sodium sulfate and concentrated under reduced 
pressure to give 1-(thiophene-2-yl)cyclohexane-1-ol as an amber oil.  
  
A solution of the crude tertiary alcohol (104 mmol, 18.94 g) in CHCl3 (50 mL) was 
added dropwise to a vigorously stirred suspension of NaN3 (208 mmol, 13.51 g) and 
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trifluoroacetic acid (312 mmol, 23.86 mL) in CHCl3 (200 mL) at 0 °C under argon. 
After addition, the suspension was allowed to recover to room temperature and stir 
for 24 hours at which point it had set to a solid mass. The reaction mixture was 
carefully quenched by slow addition to a stirred concentrated aqueous solution of 
NaHCO3. Once the evolution of gas was complete, the organic phase was collected, 
washed with dH2O and saline, dried with anhydrous sodium sulfate and concentrated 
under reduced pressure to give the crude azide as a yellow oil. The azide was 
purified using flash column chromatography on silica gel with hexanes as the mobile 
phase. Early fractions containing the azide product were pooled and concentrated to 
produce a light yellow oil (81 mmol, 16.71 g, 77.9% yield).   
  
A solution of the purified azide (81 mmol, 16.71 g) in dry THF (50 mL) was added 
dropwise over the course of an hour to a vigorously stirred suspension of LiAlH4 (242 
mmol, 9.2 g) in dry THF (200 mL) under argon at 0°C. The reaction mixture was kept 
at 0 °C for 1 h. It was then quenched by cautious dropwise addition of a 50:50 
mixture of THF and ice cold dH2O (50 mL). A few mL of aqueous KOH were added to 
ensure a basic pH and ethyl acetate (300 mL) was added and the suspension gravity 
filtered to remove insoluble inorganic salts. Inorganic salts were washed with ethyl 
acetate. The organic phase was extracted with aqueous HCl solution (3 x 200 mL), 
acidic phases pooled, made basic to pH > 12 with KOH pellets and extracted with 
ethyl acetate (3 x 70 mL). Organic phases were pooled, washed with saline, dried 
with anhydrous magnesium sulfate, gravity filtered and concentrated under reduced 
pressure to give a colorless oil. The crude product was purified by flash column 
chromatography on silica gel eluting with hexanes:ethyl acetate (3:1) containing 
0.5 % triethylamine with a gradually increasing ethyl acetate concentration to 50%. 
Desired fractions were pooled and concentrated under reduced pressure to give 1-
(thiophene-2-yl)cyclohexane-1-amine (TCA), a light yellow oil (71 mmol, 12.85 g, 
87.7% yield).  
 
The HCl salt of TCA was prepared by dissolving it in ethanol, titrating to pH 1.0 with 
concentrated HCl, and evaporating under a stream of warm air. Dry acetone (4 Å 
sieves) was added in 10 mL increments until all residual moisture and HCl was 
removed. The resulting solid was washed with ethyl acetate (2 x 5 mL), dried, and 
crystallized by dissolving in a minimal amount of warm methanol diluted with a 10-
fold excess of diethyl ether. The solution was stored at 0 oC overnight. The resulting 
crystals were collected by decanting the solvent off and then washing with ethyl 
acetate (2 x 5 mL), followed by drying in an oven at 60 oC. The solids were 
recrystallized two more times as described to produce white fluffy thin needle-like 
crystalline solids (m.p. 214.3 – 215.6 °C).  
 
Preparation of N-methyl-1-(thiophen-2-yl)cyclohexan-1-amine (TCMe) (1a) 
  
A solution of TCA (7.72 mmol, 1.40 g) and ethyl formate (10 mL) containing 4 Å 
molecular sieves (1.0 g) were refluxed under an inert atmosphere of argon. As 
solvent tended to dissipate, additional ethyl formate was added as needed to keep a 
constant volume. After ~72 h the reaction mixture was quenched by diluting in 400 
mL 1N aqueous HCl solution. This solution was extracted with ethyl acetate (3 x 60 
mL), organic phases pooled, washed with 2N aqueous HCl solution (2 x 100 mL), 
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saline (40 mL), dried and concentrated under vacuum to give N-[1-(thiophen-2-
yl)cyclohexyl]formamide (N-formyl-TCA) as a white solid (6.69 mmol, 1.40 g, 86.7 % 
yield). The solid was crystallized from hexanes containing 10% ethyl acetate followed 
by storage at 0 °C. However, the crude product was sufficient for use in the 
subsequent reaction.  
 
A solution of dry THF (40 mL) containing N-formyl-TCA (6.69 mmol, 1.40 g) was 
added dropwise to a stirred suspension of LiAlH4 (21.4 mmol, 0.8117 g) in THF (100 
mL) at 0 °C under argon. The stirred reaction mixture was then allowed to warm to 
room temperature and placed on a mild reflux while maintaining an inert argon 
atmosphere. Once complete (TLC or GC/MS), the reaction mixture was placed on ice 
and quenched by dropwise addition of a 50:50 mixture of ice cold THF and dH2O with 
vigorous stirring. The suspension was then diluted with 400 mL ethyl acetate and the 
inorganic salts removed by gravity filtration. The filtered inorganic material was 
washed heavily with ethyl acetate, and the washings combined and extracted with 
aqueous 1N HCl (3 x 200 mL). The pooled aqueous phases were then basified to 
>pH 12 with KOH pellets and extracted with ethyl acetate (3 x 60 mL). The pooled 
organic extractions were washed with saline, dried with anhydrous magnesium 
sulfate and concentrated under reduced pressure to give an amber oil. The crude 
product was purified using flash column chromatography on silica gel eluting with 
hexanes:ethyl acetate (4:1) containing 1% triethylamine. Desired fractions were 
pooled and concentrated yielding colorless TCMe oil (4.92 mmol, 960 mg, 73.5 % 
yield). HCl salt prepared as described to give a colorless needle-like crystalline solid 
(148 − 149 °C (phase transition), m.p. 194.8 − 195.9 °C). HR-ESI-MS: observed m/z 
196.11553 (theory [M + H]+: C11H18NS
+ m/z 196.11545).  
 
Preparation of N-ethyl-1-(thiophen-2-yl)cyclohexane-1-amine  (TCE) (1b) 
 
TCA (5.52 mmol, 1.0 g) was dissolved in triethylamine (1 mL) in a beaker and placed 
on ice. Under a blanket of argon gas, acetyl chloride (11.1 mmol, 0.79 mL) was 
added dropwise and mixed with a spatula until a waxy white precipitate formed. The 
solid was suspended in aqueous 2N HCl solution (100 mL) and extracted with ethyl 
acetate (3 x 75 mL). The pooled organic phases were washed with 2N aqueous HCl 
solution (2 x 30 mL), dH2O (20 mL) and saline (10 mL). The organic solution was 
dried with anhydrous sodium sulfate and concentrated under reduced pressure to 
produce N-[1-(thiophene-2-yl)cyclohexyl]acetamide (4.92 mmol, 1.10 g, 89.5 % yield). 
These crystals were recrystallized from boiling ethyl acetate and stored at 0 °C. The 
crude product was sufficient in purity for use in the subsequent reaction.  
 
A solution of N-[1-(thiophene-2-yl)cyclohexyl]acetamide (4.5 mmol, 1.0 g) in dry THF 
(20 mL) was added dropwise to a stirred suspension of LiAlH4 (13.4 mmol, 0.51 g) in 
dry THF (100 mL) on ice under argon. Upon completion of the addition, the reaction 
mixture was removed from ice and brought to a mild reflux. The reflux was continued 
and monitored for completion by TLC (~ 4 h). The reaction mixture was quenched 
with dropwise addition of a 50:50 mixture of ice cold THF and dH2O. A few drops of 
KOH solution were added and the reaction mixture diluted with ethyl acetate (200 
mL). The resulting inorganic salts were removed via gravity filtration and washed with 
ethyl acetate (150 mL). The organic phase was extracted with aqueous 1N HCl 
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solution (3 x 75 mL). The pooled aqueous phases were made basic with KOH pellets 
(pH >12) and extracted with ethyl acetate (3 x 100 mL). The pooled organic fractions 
were washed with saline (20 mL), dried with anhydrous magnesium sulfate, gravity 
filtered and concentrated under reduced pressure to produce N-ethyl-1-(thiophene-2-
yl)cyclohexane-1-amine (1b) (2.10 mmol, 0.45 g, 46.7 % yield). HCl salt prepared as 
previously described to give a colorless needle-like crystalline solid (m.p. 193.9 – 
195.1 °C; lit: 195-196 °C[22]) HR-ESI-MS: observed m/z 210.13120 (theory [M + H]+: 
C12H20NS
+ m/z 210.13110).  
 
Preparation of N-propyl-1-(thiophen-2-yl)cyclohexane-1-amine (TCPr) (1c) 
 
TCPr was prepared as described for TCE above in 92% yield from TCA (5.52 mmol, 
1.0 g) as a white crystalline solid. Generation of the HCl salt gave a colorless needle-
like crystalline solid (116 − 117 °C (phase transition), m.p. 183.8 − 185.5 °C). HR-
ESI-MS: observed m/z 224.1465 (theory [M + H]+: C13H22NS
+ m/z 224.1467).  
 
Preparation of 1-(2-methoxyphenyl)cyclohexan-1-amine (2-MeO-PCA)  
 
2-MeO-PCA was prepared in 54.8% yield from cyclohexanone (26.6 mmol, 2.61 g) 
and 2-bromoanisole (31.9 mmol, 5.96 g) as described for TCA above. The HCl salt 
was prepared as described for 3-MeO-PCA to give colorless needles with a melting 
point of 176.7 − 178.0 °C (lit: 212-215 °C[23]).  
 
Preparation of N-methyl-1-(2-methoxyphenyl)cyclohexan-1-amine (2-MeO-PCMe) 
(2a) 
 
N-[1-(2-methoxyphenyl)cyclohexyl]formamide (N-formyl-2-MeO-PCA) was prepared 
as previously described in 67.7 % yield from 2-MeO-PCA (5.21 mmol, 1.07 g) as a 
white solid. 2-MeO-PCMe was obtained as described in 16.9% yield from N-formyl-2-
MeO-PCA (0.86 mmol, 0.20 g), as a colorless oil. The HCl salt was obtained as a 
white crystalline solid; 107 − 110 °C (phase transition), m.p. 185 − 187 °C. HR-ESI-
MS: observed m/z 220.16982 (theory [M + H]+: C14H22NO
+ m/z 220.16959).  
 
Preparation of N-ethyl-1-(2-methoxyphenyl)cyclohexan-1-amine (2-MeO-PCE) (2b) 
 
N-[1-(2-methoxyphenyl)cyclohexyl]acetamide (N-acetyl-2-MeO-PCA) was prepared 
as previously described in 93.6 % yield from 2-MeO-PCA (5.50 mmol, 1.13 g) as a 
white solid. 2-MeO-PCE freebase was prepared as described in 91.2% yield from N-
acetyl-2-MeO-PCA (3.92 mmol, 0.97 g) as a colorless oil. The sparkling white 
crystalline HCl salt gave a m.p. of 194.3 − 195.9 °C. HR-ESI-MS: observed m/z 
234.18520 (theory [M + H]+: C15H24NO
+ m/z 234.18524). 
 
Preparation of N-propyl-1-(2-methoxyphenyl)cyclohexan-1-amine (2-MeO-PCPr) (2c) 
 
N-[1-(2-methoxyphenyl)cyclohexyl]propanamide (N-propionyl-2-MeO-PCA) was 
prepared as previously described in 88.0 % yield from 2-MeO-PCA (5.41 mmol, 1.11 
g) as a white solid. 2-MeO-PCPr was prepared as described in 28.9% yield from N-
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propionyl-2-MeO-PCA (1.34 mmol, 0.35 g), as a colorless oil. The HCl salt was a 
sparkling white crystalline solid (m.p. 213.5 − 214.5 °C). HR-ESI-MS: observed m/z 
248.20086 (theory [M + H]+: C16H26NO
+ m/z 248.20089). 
 
Preparation of 1-(3-methoxyphenyl)cyclohexan-1-amine (3-MeO-PCA) 
 
3-MeO-PCA was prepared in 61.0% yield from cyclohexanone (53.0 mmol, 5.23 g) 
and 3-bromoanisole (64.0 mmol, 11.97 g). The HCl salt of 3-MeO-PCA was prepared 
as described previously (m.p. 197.0 − 197.7 °C[4]; lit: 195 − 196 °C[23]).  
 
Preparation of N-methyl-1-(3-methoxyphenyl)cyclohexan-1-amine (3-MeO-PCMe) 
(3a) 
  
N-[1-(3-methoxyphenyl)cyclohexyl]formamide (N-formyl-3-MeO-PCA) was prepared 
as previously described in 97.0% yield from 3-MeO-PCA (10.2 mmol, 2.10 g) as a 
white solid. 3-MeO-PCMe was prepared as described in 79.0% yield from N-formyl-3-
MeO-PCA (9.94 mmol, 2.32 g), as colorless oil. The HCl salt of 3-MeO-PCMe (3a) 
was prepared and recrystallized twice from methanol/diethyl ether at 0 °C to give a 
colorless, crystalline solid (m.p. 214.5 − 217.0 °C). HR-ESI-MS: observed m/z 
220.16948 (theory [M + H]+: C14H22NO
+ m/z 220.16959). 
 
Preparation of N-ethyl-1-(3-methoxyphenyl)cyclohexan-1-amine (3-MeO-PCE) (3b) 
 
N-[1-(3-methoxyphenyl)cyclohexyl]acetamide (N-acetyl-3-MeO-PCA) was prepared 
as previously described in 99.1% yield from 3-MeO-PCA (6.33 mmol, 1.30 g) as a 
deep orange oil. 3-MeO-PCE prepared in 55.3% yield as described from N-acetyl-3-
MeO-PCA (1.82 mmol, 0.45 g). HCl salt was prepared to give a white crystalline solid, 
m.p. 214.0 − 215.5 °C. HR-ESI-MS: observed m/z 234.18519 (theory [M + H]+: 
C15H24NO
+ m/z 234.18524). 
 
Preparation of N-propyl-1-(3-methoxyphenyl)cyclohexan-1-amine (3-MeO-PCPr) (3c) 
 
N-[1-(3-methoxyphenyl)cyclohexyl]propanamide (N-propionyl-3-MeO-PCA) was 
prepared as previously described in 91.0% yield from 3-MeO-PCA (6.33 mmol, 1.30 
g) as an orange colored oil. 3-MeO-PCPr prepared as described in 75.5% yield from 
N-propionyl-3-MeO-PCA (3.82 mmol, 1.0 g) as a colorless oil. HCl salt was prepared 
as described to give a white crystalline solid, m.p. 181.0 − 183.0 °C. HR-ESI-MS: 
observed m/z 248.20063 (theory [M + H]+: C16H26NO
+ m/z 248.20089). 
 
Preparation of 1-(4-methoxyphenyl)cyclohexan-1-amine (4-MeO-PCA) 
 
4-MeO-PCA was prepared as previously described in 49.0% yield from 
cyclohexanone (41.5 mmol, 4.07 g) and 4-bromoanisole (49.7 mmol, 9.30 g) as 
colorless oil. HCl salt was prepared to give a thin needle-like crystalline solid, m.p. 
251.1 − 252.0 °C (Lit: 233 − 234 °C[23])  
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Preparation of N-methyl-1-(4-methoxyphenyl)cyclohexan-1-amine (4-MeO-PCMe) 
(4a) 
 
N-[1-(4-methoxyphenyl)cyclohexyl]formamide (N-formyl-4-MeO-PCA) was prepared 
as previously described in 87.0 % yield from 4-MeO-PCA (5.16 mmol, 1.06 g) as a 
white solid. 4-MeO-PCMe was prepared in 39.5% yield from N-formyl-4-MeO-PCA 
(3.34 mmol, 0.780 g), as a colorless oil. HCl salt was prepared as described to give a 
sparkling colorless needle-like solid, m.p. 164.0 − 165.7 °C. HR-ESI-MS: observed 
m/z 220.1964 (theory [M + H]+: C14H22NO
+ m/z 220.1696). 
 
Preparation of N-ethyl-1-(4-methoxyphenyl)cyclohexan-1-amine (4-MeO-PCE) (4b) 
 
N-[1-(4-methoxyphenyl)cyclohexyl]acetamide (N-acetyl-4-MeO-PCA) was prepared 
as previously described in 90.5 % yield from 4-MeO-PCA (6.92 mmol, 1.42 g) as a 
white solid. 4-MeO-PCE was prepared as described in 50.8% yield from N-acetyl-4-
MeO-PCA (2.42 mmol, 0.60 g), as a colorless oil. HCl salt was prepared as 
described to give a sparkling white crystalline solid, m.p. 189.0 − 191.8 °C. HR-ESI-
MS: observed m/z 234.1850 (theory [M + H]+: C15H24NO
+ m/z 234.1852). 
 
Preparation of N-propyl-1-(4-methoxyphenyl)cyclohexan-1-amine (4-MeO-PCPr) (4c) 
 
N-[1-(4-methoxyphenyl)cyclohexyl]propanamide (N-propyl-4-MeO-PCA) was 
prepared as previously described in 86.0 % yield from 4-MeO-PCA (6.82 mmol, 1.40 
g) as a white solid. 4-MeO-PCPr was prepared as described in 39.4% yield from N-
proply-4-MeO-PCA (2.30 mmol, 0.60 g), as a colorless oil. HCl salt was prepared as 
described to give a sparkling white crystalline solid, m.p. 184.8 − 186.3 °C. HR-ESI-
MS: observed m/z 248.2006 (theory [M + H]+: C16H26NO
+ m/z 248.2009). 
 
Preparation of 1-(3-methylphenyl)cyclohexan-1-amine (3-Me-PCA) 
 
3-Me-PCA was prepared as described in 70.2% yield from cyclohexanone (25.0 
mmol, 2.45 g) and 3-bromotoluene (30.0 mmol, 5.13 g) as colorless oil. HCl salt was 
prepared to give a white fluffy crystalline solid, m.p. 209 − 212 °C (Lit: 209 
− 210 °C[23]).  
 
Preparation of N-methyl-1-(3-methylphenyl)cyclohexan-1-amine (3-Me-PCMe) (5a) 
 
N-[1-(3-methylphenyl)cyclohexyl]formamide (N-formyl-3-Me-PCA) was prepared as 
previously described in 95.9% yield from 3-Me-PCA (11.1 mmol, 2.1 g) as a light 
yellow oil. 3-Me-PCMe was prepared as described in 59.0% yield from N-formyl-3-
Me-PCA (10.6 mmol, 2.31 g), as a colorless oil. HCl salt was prepared to give fluffy 
colorless needle-like crystalline solid, m.p. 213.3 − 215.5 °C. HR-ESI-MS: observed 
m/z 204.17439 (theory [M + H]+: C14H22N
+ m/z 204.17468). 
 
Preparation of N-ethyl-1-(3-methylphenyl)cyclohexan-1-amine (3-Me-PCE) (5b) 
 
Page 9 of 34
http://mc.manuscriptcentral.com/dta
Drug Testing and Analysis
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
 9
N-[1-(3-methylphenyl)cyclohexyl]acetamide (N-acetyl-3-Me-PCA) was prepared as 
described in 95.5% yield from 3-Me-PCA (5.28 mmol, 1.0 g) as an orange crystalline 
solid. 3-Me-PCE prepared as described in 76.4% yield from N-acetyl-3-Me-PCA 
(6.48 mmol, 1.50 g), as a colorless oil. HCl salt was prepared to give a white 
crystalline solid, m.p. 234.1 − 235.0 °C (Lit: 236 − 237 °C[24]). HR-ESI-MS: observed 
m/z 218.19030 (theory [M + H]+: C15H24N
+ m/z 218.19033). 
 
Preparation of N-propyl-1-(3-methylphenyl)cyclohexan-1-amine (3-Me-PCPr) (5c) 
 
N-[1-(3-methylphenyl)cyclohexyl]propanamide (N-propionyl-3-Me-PCA) was 
prepared as previously described in 86.5 % yield from 3-Me-PCA (5.28 mmol, 1.0 g) 
as a white solid. 3-Me-PCPr was prepared as described in 65.0% yield from N-
propionyl-3-Me-PCA (5.30 mmol, 1.30 g), as a colorless oil. HCl salt was prepared to 
give a fluffy white crystalline solid, m.p. 226.0 − 226.8 °C. HR-ESI-MS: observed m/z 
232.20588 (theory [M + H]+: C16H26N
+ m/z 232.20598). 
 
Instrumentation 
 
Nuclear magnetic resonance spectroscopy  
 
1H (400 MHz) and 13C NMR spectra (100 MHz) were obtained from the hydrochloride 
salts in CDCl3 solutions (100% and 99.96% D, 0.03% (v/v) TMS) on a Bruker 
Ultrashield 400 plus spectrometer with a 5 mm BBO S1 (Z gradient plus) probe at 
24 °C.  Internal chemical shift references were TMS (δ = 0.00 ppm) and solvent (δ = 
77.0 ppm).  
 
Gas chromatography ion trap mass spectrometry 
 
Data for all fifteen N-alkyl-arylcyclohexylamines (0.5 mg/mL in methanol) were 
recorded under full can electron (EI) and chemical ionization (CI) conditions using 
HPLC grade methanol as the liquid CI reagent. A Varian 450-GC gas chromatograph 
coupled to a Varian 220-MS ion trap mass spectrometer and a Varian 8400 
autosampler was employed with a Varian CP-1177 injector (275 ºC) in split mode 
(1:50) (Walnut Creek, CA, USA). The Varian MS Data Review function of the 
Workstation software, version 6.91, was used for data acquisition. Transfer line, 
manifold and ion trap temperatures were set at 310, 80 and 220 ºC, respectively. The 
carrier gas was helium at a flow rate of 1 mL/min using the EFC constant flow mode. 
The default settings for CI ionization parameters (0.4 s/scan) were used: CI storage 
level m/z 19.0; ejection amplitude m/z 15.0; background mass m/z 55; maximum 
ionization time 2000 µs; maximum reaction time 40 ms; target TIC 5000 counts. An 
Agilent J&W VF-5ms GC column (30 m × 0.25 mm, 0.25 µm) was employed for 
separation. The starting temperature was set at 130 ºC and held for 1 min. The 
temperature then increased at 20 ºC/min to 280 ºC and held constant for 11.50 min 
to give a total run time of 20.00 min. 
Electrospray triple quadrupole mass spectrometry 
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Electrospray triple quadrupole tandem mass spectrometry experiments were carried 
out by direct infusion (10 L/min at 0.01 mg/mL) of (1a) – (5c) compounds using a 
Waters Micromass Quattro Premier triple quadrupole MS/MS system (Waters 
Micromass, Manchester, UK) and the Masslynx version 4.1 software. Optimization of 
signal intensities were performed in positive MS scan and in product ion scan mode. 
The optimized source conditions were as follows: capillary 3.12 kV, rf lens 0.1 V, 
source temperature 100 °C, desolvation temperature 200 °C and the multiplier 
voltage was 650 V. Nitrogen was used as the cone gas (50 L/h) and desolvation gas 
(200 L/h) whilst the collision gas was argon (0.3 mL/min flow). The [M + H]+ ion 
corresponding to all fifteen substances were selected for MS/MS experiments. 
Product ions were collected over the range m/z 50 and m/z 250. Scan time for each 
channel was 0.5 s and interscan delay was 0.1 s. The cone voltage and collision 
energy values were as follows: 10 V and 18 eV for (1a) – (1c); 18 V and 15 eV for all 
three sets of methoxyphenyl substituted isomers; 15 V and 15 eV for (5a) and (5c) 
and 15 V and 12 eV for (5b), respectively. 
 
High-resolution electrospray mass spectrometry  
Analyses were carried out by characterization using UHPLC-QTOF-MS/MS as 
described previously.[25,26] Briefly, mobile phases used for UHPLC separation 
consisted of 100% acetonitrile (1% formic acid) and an aqueous solution of 1% 
formic acid. The column temperature was set at 40 °C (0.6 mL/min) and data were 
acquired for 5.5 min. The elution was a 5–70% acetonitrile gradient ramp over 3.5 
min, then increased to 95% acetonitrile in 1 min and held for 0.5 min before returning 
to 5% acetonitrile in 0.5 min. QTOF-MS data were acquired in positive mode 
scanning from m/z 100 – m/z 1000 with and without auto MS/MS fragmentation. 
Ionization was achieved with an Agilent JetStream electrospray source and infused 
internal reference masses. Agilent 6540 QTOF-MS parameters: gas temperature 
325 °C, drying gas 10 L/min and sheath gas temperature 400 °C. Internal reference 
ions at m/z 121.05087 and m/z 922.00979 were used.   
 
High performance liquid chromatography diode array detection 
HPLC-DAD analyses[25,26] were carried out on a Dionex 3000 Ultimate system 
coupled to a UV diode array detector (Thermo Fisher, St Albans, UK), using a 
Phenomenex Synergi Fusion column (150 mm x 2 mm, 4 µm) that was protected by 
a 4 mm x 3 mm Phenomenex Synergi Fusion guard column (Phenomenex, 
Macclesfield, UK). The mobile phases were made from 70% acetonitrile with 25 mM 
TEAP buffer and an aqueous solution of 25 mM TEAP buffer. Elution was achieved 
with a gradient that started with 4% acetonitrile and ramped to 70% acetonitrile in 15 
min and held for 3 min. The total acquisition time was 18 min at a flow rate of 0.6 
mL/min. The diode array detection window was set at 200 nm to 595 nm (collection 
rate 2 Hz). 
 
Infrared spectroscopy 
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Infrared (IR) spectra were obtained on a Perkin Elmer Spectrum BX FTIR model 
(Llantrisant, UK) using a Pike MIRacle ATR system. Data were acquired with the 
Spectrum v5.01 software (scan range 4000–400 cm-1, resolution 4 cm-1, 16 scans). 
 
Results and discussion 
 
A number of routes exist for the syntheses of arylcyclohexylamines.[1,27] In the 
present study, primary amines were synthesized using modified Geneste route 
(Figure 2B)[28], similar to the approach taken in previous work on PCP and 1-(1-
phenylcyclohexyl)pyrrolidine (PCPy) analogs.[4] It has been found in practice that the 
primary amines represent practical intermediates to prepare appropriately substituted 
secondary and tertiary amines. Secondary amines were synthesized by conversion 
to the amide, which was found to be high yielding. Subsequent reduction of the 
amide gave the desired N-alkyl secondary amines (1a) – (5c) in moderate to good 
yields.  
 
The syntheses of primary amine intermediates 3-Me-PCA, 2-MeO-PCA, 3-MeO-PCA, 
4-MeO-PCA and TCA have been described previously,[22,23,29,30] and these were 
based on the implementation of the Geneste route in most cases. A modified imine 
(sulfinimine) route has been described for 3-MeO-PCA[31] and a route via an imine 
stage was employed before for the preparation of secondary amine compounds 
carrying a 3-methoxyphenyl substituent.[32] The preparation of secondary amines 
from primary amine intermediates via alkylation with the appropriate alkyl halide was 
also reported for TCMe (1a), TCE (1b) and TCPr (1c).[30,33] The syntheses of the 
methoxy isomers was described in 1988 using an imine route.[32]  
 
The characterization of a number of compounds appeared to be unreported in the 
existing literature, such as 2-MeO-PCE (2b), 2-MeO-PCPr (2c), 3-Me-PCPr (5c), and 
4-MeO-PCPr (4c). Likewise, 2-MeO-PCMe (2a) and 4-MeO-PCMe (4a) do not 
appear in the literature but are apparently available commercially. It was previously 
suggested[1] that 3-MeO-PCE (3b), and 3-MeO-PCPr (3c) had not been described in 
the scientific literature prior to their non-medical use. However, it was noticed that 
these were in fact described in a 1988 conference proceedings held by researchers 
at Eli Lilly. Both compounds showed NMDA receptor affinity and in vivo activity 
consistent with NMDA receptor antagonism.[32]  
 
Chromatography and mass spectrometry 
 
Gas chromatography retention times and ion trap (IT) electron (EI) and chemical 
ionization (CI) mass spectral data (GC-IT-MS) are summarized in Figures 3 and 4. 
The proposed mechanism for EI-induced formation of base peak ions, which may 
have involved the loss of a propyl radical from the cyclohexyl component, was 
adapted from previously published work and is shown in Figure 5A[4]. The EI and CI 
mass spectra recorded for 3-MeO-PCE (3b) (Figure 3H1/H2) were comparable to 
previously published data[20] but some differences in relative abundance values were 
also visible, which might have been associated with the ion trap mass analyzer. For 
example, under the conditions used, the implementation of GC ion trap EI-MS 
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frequently resulted in the formation of what appeared to be the protonated molecule 
instead of the M•+ ion. In some cases, formation of the [M + H]+ ion formed the base 
peak similar to what was observed previously during the analysis of methoxetamine 
(MXE).[20,34] In the present study, it was noticed that [M + H]+ ions were particularly 
abundant in the EI-IT-MS spectra of the 2-methoxyphenyl substituted compounds 
(2a) – (2c) (Figure 3D1, 3E1 and 3F1). Self-ionization was not observed in any EI 
mass spectra recorded with a quadrupole mass analyzer where M•+ ions were 
detectable in appreciable abundance (supplementary information).   
 
When inspecting the EI-IT mass spectra for potential differences between N-methyl 
substituted isomers (2a, 3a and 4a), it was observed that an ion at m/z 189 was 
particularly abundant in the EI-IT mass spectrum of 4-MeO-PCMe (4a) (Figure 4J1) 
and that it was absent when using a quadrupole mass analyzer (supplemental data). 
Figure 5B shows a suggested mechanism that may account for this observation 
following the neutral loss of formaldehyde (CH2O) within the ion trap. The ortho- and 
meta isomers (2a and 3a) (Figure 3D1 and 3G1) indicated a reduced formation of 
m/z 189 which may be explained by the proximity of the 2-OCH3 group to the terminal 
methylene radical. Interestingly, the isomers 2-, 3-, and 4-MeO-PCE (2b, 3b and 4b) 
did not display this phenomenon, whereas the three N-propyl substituted PCPr 
counterparts (2c, 3c and 4c) formed this ion. Similarly, the most abundant m/z 189 
species was observed in the spectrum of 4-MeO-PCPr (4c) (Figure 4L1), whereas it 
showed a relatively low abundance under quadrupole conditions (supplementary 
information). The CI-IT-MS spectra (Figures 3 and 4) yielded the expected [M + H]+ 
ions and additional formation of an even-electron ion following the loss of the 
corresponding amine. In this case, the associated ions were formed at m/z 165 (1a) – 
(1c), m/z 189 (2a) – (4c) and m/z 173 (5a) – (5c), respectively (Figure 5C) and were 
presumably similar to the species observed under electrospray ionization conditions 
(see below).   
 
Interestingly, the CI-IT mass spectra recorded for 2-methoxyphenyl substituted 
substances (2a, 3a and 4a) differed from their isomeric representatives by the 
relative abundance of the m/z 189 ion and the corresponding protonated molecules. 
The meta- and para-substituted compounds appeared to display a decrease in 
relative abundance of [M + H]+ relative to m/z 189 in the order of 2-MeO-PCMe (2a) 
(Figure 3D2) > 3-MeO-PCMe (3a) (Figure 3G2) > 4-MeO-PCMe (4a) (Figure 4J2), 
respectively. A potential reason for what appeared to be increased stability of 2-MeO-
PCMe (2a) may have been related to stabilization and increased charge distribution, 
thus, possibly rendering the protonated molecule more stable (Figure 5D). In 
addition, all CI-IT mass spectra obtained from the three 2-methoxyphenyl analogs 
also displayed an ion at m/z 121 that was either less prominent or absent in the 
spectra of the meta- and para substituted analogs. Figure 5E depicts an attempt to 
rationalize its formation, which might require the presence of the 2-methoxyphenyl 
position.      
 
Representative electrospray ionization (ESI) triple quadrupole (QqQ) tandem mass 
spectra and ion ratios for the 2-MeO-, 3-MeO-, and 4-MeO-PCE isomers (2b, 3b and 
4b) following direct infusion are presented in Figure 6A−C. Collision-induced 
dissociation (CID) of the product ions gave primarily rise of two product ions at m/z 
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189 and m/z 121 that might be suitable for implementing the corresponding ion 
transitions for screening purposes. In case of 3-MeO-PCE (3b), these two main ions 
were also observed previously using a triple-quadrupole linear ion trap mass 
spectrometer. Correspondingly, the remaining ring-substituted PCMe (2a, 3a and 4a) 
and PCPr isomers (2c, 3c and 4c) also yielded the m/z 189 and m/z 121 ions 
(supplemental data). Examination of the QqQ spectra in Figure 6A−C also revealed 
the presence of a product ion at m/z 81 in the spectra of 3-MeO-, and 4-MeO-PCE 
(3b, 4b) that was absent in the QqQ tandem mass spectrum of 2-MeO-PCE (2b) 
(Figure 6A). Given that the tandem mass spectra were recorded under identical 
conditions and collision energies, it was tempting to consider the potential for 
differentiation between the three PCE isomers based on distinct ion ratios alone. The 
QqQ tandem mass spectrum of 3-MeO-PCE (3b) showed an increased abundance 
of the m/z 81 species compared to 4-MeO-PCE (4b) (Figure 6B/6C). Interestingly, 
the differential formation of m/z 81 was equally observed in the tandem mass spectra 
of the ring-substituted PCMe (2a, 3a and 4a) and PCPr isomers (2c, 3c and 4c) as 
well (supplemental data). The ultra high performance liquid chromatography 
(UHPLC) ESI quadrupole-time-of-flight (Q-TOF) tandem mass spectra for 3-MeO-, 
and 4-MeO-PCE (2b, 3b) are shown in Figure 6D/7E. Due to extensive in-source CID 
of the protonated molecule of 4-MeO-PCE (3b) (Figure 6F), a tandem mass 
spectrum of the m/z 189.12746 base peak was recorded as shown in Figure 6G. As 
observed in the QqQ tandem mass spectra of the 12 remaining N-alkyl 
arylcyclohexylamines (supplementary information), formation of the suggested 
cyclohexen-1-ylium ion at m/z 81 was also frequently detected. The acquisition of 
high mass accuracy Q-TOF data was considered helpful for the proposal of 
suggested structural representations associated with m/z 81, m/z 121 and m/z 189, 
respectively (Figure 7).  
 
Implementation of the HPLC-DAD and UHPLC-Q-TOF-MS methods provided 
separation of the 2-MeO substituted N-alkyl arylcyclohexylamines (2a−2c) from their 
3-MeO-, and 4-MeO counterparts (3a−3c) and (4a−4c), respectively. Co-elution, 
however, was observed for the latter two groups of meta- and para-substituted 
methoxyphenyl candidates (Figure 6 and supplementary information). Figure 8 
shows the retention times and overlaid diode array spectra (DAD) obtained from PCE 
isomers (2b), (3b) and (4b), which demonstrated that the availability of full scan 
ultraviolet information facilitated differentiation between the co-eluting isomers. 
Similarly, the differentiation between the remaining 3-methoxy and 4-methoxyphenyl 
isomers (3a/4a) and (3c/4c) was also successful under DAD conditions and the 
corresponding spectra are shown as supplementary information. The use of HPLC-
DAD has been increasingly helpful when applied to a number of investigations that 
investigated the presence and characterization of ring-substituted isomers.[6,35] In 
addition, the infrared spectra for all substances have been supplied as 
supplementary information, which confirmed that the isomeric 2-, 3- and 4-methoxy 
phenylcyclohexylamines could be differentiated, for example in the form of shifting 
wavenumbers associated 1,2-, 1,3-, and 1,4-disubstituted benzenes.[36] This was in 
agreement with shift changes observed with 2-, 3-, and 4-methylphenyl substituted 
PCP isomers.[37]     
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Nuclear magnetic resonance spectroscopy 
 
Chemical shifts were assigned using chemical shift position, splitting pattern, 13C 
polarization enhancement nurtured during attached nucleus testing (PENDANT) and 
2-D techniques (HMQC, HMBC, COSY-90) similar to the approach taken previously 
for tertiary amine-based PCP and PCPy derivatives.[4] A representative example of 
an HMQC spectrum for 3-MeO-PCPr (3c) is shown in Figure 9. While some of the 
present compounds have been described for a range of investigations, limited 
information appeared available on the analytical properties including detailed NMR 
analysis. For example, NMR data were reported for thiophene compounds (1a) – 
(1c)[33,38] and 3-MeO-PCE (3b)[20] but without chemical shift assignments, which are 
provided here. The NMR data associated with the primary amine intermediates and a 
more detailed discussion of the NMR chemical shift behavior is presented in the 
supplemental section.  
 
Proton chemical shifts 
 
All proton chemical shift values, multiplicities and assignments for 
arylcyclohexylamines (1a) – (5c) are summarized in Tables 1–3.  
 
Identification of positional isomers is an important requirement of forensic 
identification. The three positional methoxyphenyl isomers could be readily 
distinguished by inspecting the downfield aromatic regions of the 1H proton spectra. 
Aromatic multiplicities exhibited 2J and 3-4J couplings. The multiplets linked to the 
para-substituted isomers were readily identified by a characteristic pair of doublets of 
multiplets that represented the aromatic protons due to additional splitting of the 
doublets by long-range couplings. The chemical shifts obtained from 2-, and 3-
methoxyphenyl isomers were readily distinguishable in all equivalent N-alkyl pairs as 
a reflection of the position on the phenyl ring (Tables 1–3).  
 
Carbon chemical shifts 
 
All chemical shift data are summarized in Tables 4–6.  
 
13C chemical shifts were also useful in distinguishing the methoxyphenyl isomers. 
Due to the symmetry of para-substituted aryl rings, the 4-methoxyphenyl isomers 
displayed four separate aromatic 13C chemical shifts; C1’, C2’-C6’, C3’-C5’, and C4’. The 
2- and 3-methoxyphenyl counterparts showed six distinct aromatic 13C chemical 
shifts. Another distinguishing feature was the C1’ chemical shift value. In the spectra 
of 2- and 4-methoxyphenyl isomers, an upfield shift >10 ppm was observed when 
compared to the meta-substituted series, presumably due to enhanced shielding and 
electron density from resonance contributions.  
 
Conclusion 
 
Newly emerging psychoactive substances continue to remain a challenge for forensic 
scientists, clinicians and policy makers. The syntheses and comprehensive analytical 
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characterizations of 15 N-alkyl-arylcyclohexylamines included a range of ‘research 
chemical’ analogues that have not yet been described in detail. It was also 
demonstrated that positional isomers could be differentiated using analytical 
techniques typically involved in forensic and clinical casework.  
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Figure captions 
 
Figure 1. Phencyclidine (PCP) and other representative arylcyclohexylamine and 1,2-
diphenylethylamine examples associated with the recreational ‘research chemicals’ 
market.   
 
Figure 2. A: Fifteen N-alkyl-arylcyclohexylamines subjected to synthesis and 
analytical characterizations. B: Synthetic routes employed for the preparation of (1a) 
– (5c) 
 
Figure 3. Gas chromatography retention times and ion trap (IT) mass spectra 
obtained in electron (EI) and chemical ionization (CI) mode. 
 
Figure 4. Gas chromatography retention times and ion trap (IT) mass spectra 
obtained in electron (EI) and chemical ionization (CI) mode. 
 
Figure 5. Suggested key ions following mass spectral detection under EI and CI 
conditions. 
 
Figure 6. A-C: Electrospray ionization triple quadrupole mass spectra of three 
positional N-ethyl-1-phenylcyclohexan-1-amine (PCE) isomers. D-G. Ultra-high 
performance liquid chromatography quadrupole time of flight tandem mass spectra. 
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Figure 7. Suggested key ions following mass spectral detection under electrospray 
ionization conditions.  
 
Figure 8. Ultraviolet full scan spectra of N-ethyl-1-phenylcyclohexan-1-amine (PCE) 
isomers by high-performance liquid chromatography coupled to diode array detection. 
 
Figure 9. Heteronuclear single quantum coherence spectrum (HSQC) of 3-MeO-
PCPr. 
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Figure 1. Phencyclidine (PCP) and other representative arylcyclohexylamine and 1,2-diphenylethylamine 
examples associated with the recreational ‘research chemicals’ market.    
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Figure 2. A: Fifteen N-alkyl-arylcyclohexylamines subjected to synthesis and analytical characterizations. B: 
Synthetic routes employed for the preparation of (1a) – (5c)  
207x225mm (300 x 300 DPI)  
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Table 1. 400 MHz 
1
H NMR spectra of HCl salts in CDCl3. 
 
            
                                                                            
Proton TCMe (1a) 2-MeO-PCMe (2a) 3-MeO-PCMe (3a) 4-MeO-PCMe (4a) 3-Me-PCMe (5a) 
H2,6 2.59 d (13.0 Hz, 2Heq) 
2.32–2.18 m (2Hax) 
2.67 d (12.7 Hz, 2Heq) 
2.51–2.24 m (2Hax) 
2.61 d (12.9 Hz, 2Heq) 
2.41–2.12 m (2Hax) 
2.62 d (12.8 Hz, 2Heq) 
2.28–2.15 m (2Hax) 
2.62 d (13.2 Hz, 2Heq) 
2.33–2.19 m (2Hax) 
H3,5 1.92–1.73 m (2Heq) 
1.60–1.34 m (2Hax) 
1.99–1.80 m (2Heq) 
1.46–1.27 m (2Hax) 
2.03–1.76 m (2Heq) 
1.45–1.31 m (2Hax) 
1.90–1.75 m (2 Heq) 
1.35 m (2Hax) 
1.93–1.77 m (2Heq) 
1.38 qt (13.4, 3.4 Hz, 
2Hax) 
H4 1.66–1.54  m (1Heq) 
1.60–1.34 m (1Hax)  
1.71–1.56 m (1Heq) 
1.53 qt (11.7, 3.8 Hz, 1Hax) 
1.64–1.45 m (1Heq) 
1.52 qt (12.6, 3.6 Hz, 1Hax) 
1.63–1.52 m (1Heq) 
1.48 qt (12.8, 3.7 Hz, 1Hax) 
1.64–1.45 m (2H) 
H1’ – – – – – 
H2’ 7.42 dd (3.7, 1.2 Hz) – 7.37 t (2.2 Hz) 7.64 dm (8.9 Hz) 7.57 s 
H3’ 7.09 dd (5.1, 3.7 Hz) 6.99 dd (8.0, 1.0 Hz) – 6.98 dm (8.9 Hz) – 
H4’ 7.38 dd (5.1, 1.2 Hz) 7.42–7.35 m 6.91 ddd (8.3, 2.5, 1.0 Hz) – 7.50 d (7.8 Hz) 
H5’  7.03 td (7.6, 1.2 Hz) 7.34 t (8.0 Hz) 6.98 dm (8.9 Hz) 7.34 t (7.8 Hz) 
H6’ – 7.42–7.35 m 7.22 ddd (7.8, 2.0, 0.9 Hz) 7.64 dm (8.9 Hz) 7.18 d (7.8 Hz) 
Hα 2.34 s (CH3) 2.32 s  (CH3) 2.23 s  (CH3) 2.23 s  (CH3) 2.23 s  (CH3) 
Hβ – – – – – 
Hγ – – – – – 
Hc – 4.04 s (OCH3) 3.90 s (OCH3) 3.83 s (OCH3) 2.62 s (CH3) 
NH
+
 9.73 s (NH2
+
) 9.30 s (NH2
+
) 9.60 s (NH2
+
) 9.53 s (NH2
+
) 9.58 s (NH2
+
) 
* b = broad; d = doublet; m = multiplet; s = singlet; triplet; q = quartet; quint = quintet; sex = sextet  
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Table 2. 400 MHz 
1
H NMR spectra of HCl salts in CDCl3. 
Proton TCE (1b) 2-MeO-PCE (2b) 3-MeO-PCE (3b) 4-MeO-PCE (4b) 3-Me-PCE (5b) 
H2,6 2.73 d (13.0 Hz, 2Heq) 
2.39 td (12.5, 3.7 Hz, 2Hax) 
2.61 d (12.7 Hz, 2Heq) 
2.45 td (12.6, 3.9 Hz, 2Hax) 
2.77 d (13.0 Hz, 2Heq) 
2.34 td (13.3, 3.7 Hz, 2Hax) 
2.80 d (12.6 Hz, 2Heq) 
2.33 td (13.1, 3.4 Hz, 2Hax) 
2.81 d (12.6 Hz, 2Heq) 
2.35 td (13.1, 3.6 Hz, 
2Hax) 
H3,5 1.86–1.72 m (2Heq) 
1.54–1.34 m (2Hax) 
1.94–1.82 m (2Heq) 
1.46–1.28 m (2Hax) 
1.88–1.72 m (2Heq) 
1.35 qt (12.8, 3.3 Hz, 2Hax) 
1.89–1.70 m (2Heq) 
1.29 qt (12.9, 3.4 Hax) 
1.87–1.72 m (2Heq) 
1.31 qt (13.0, 3.2 Hz, 
2Hax) 
H4 1.69–1.53 m (1Heq) 
1.54–1.34 m (1Hax) 
1.65–1.57 m (1Heq) 
1.52 qt (11.7, 4.1 Hz, 1 Hax) 
1.67–1.56 m (1Heq) 
1.48 qt (12.4, 3.8 Hz, 1Hax) 
1.66–1.54 m (1Heq) 
1.48 qt (12.8, 3.8 Hz, 1Hax) 
1.70–1.54 m (1Heq) 
1.47 qt (12.4, 3.8 Hz, 
1Hax) 
H1’ – – – – – 
H2’ 7.48 dd (3.8, 1.1 Hz) – 7.47 t (2.1 Hz) 7.71 dm (8.9 Hz) 7.65 s 
H3’ 7.10 dd (5.2, 3.6 Hz) 7.01 dd (8.0, 0.9 Hz) – 6.99 dm (8.9 Hz) – 
H4’ 7.39 dd (5.2, 1.1 Hz) 7.40–7.35 m 6.92 ddd (8.1, 2.5, 1.0 Hz) – 7.57 d (7.9 Hz) 
H5’  7.06 td (7.6, 1.1 Hz) 7.36 t (8.0 Hz) 6.99 dm (8.9 Hz) 7.35 t (7.7 Hz) 
H6’ – 7.40–7.35 m 7.30 d (7.7 Hz) 7.71 dm (8.9 Hz) 7.18 d (7.6 Hz) 
Hα 2.80–2.68 m (CH2) 2.69 bs (CH2) 2.69–2.53 m (CH2) 2.68-2.53 m (CH2) 2.67–2.51 m (CH2) 
Hβ 1.42 t (7.3 Hz, CH3) 1.36 t (7.3 Hz, CH3) 1.38 t (7.3 Hz, CH3) 1.29 t (7.3 Hz, CH3) 1.38 t (7.3 Hz, CH3) 
Hγ – – – – – 
Hc – 4.01 s (OCH3) 3.91 s (OCH3) 3.83 s (OCH3) 2.43 s (CH3) 
NH
+
 9.63 s (NH2
+
) 9.20 bs (NH2
+
) 9.53 s (NH2
+
) 9.45 s (NH2
+
) 9.50 s (NH2
+
) 
* b = broad; d = doublet; m = multiplet; s = singlet; triplet; q = quartet; quint = quintet; sex = sextet. 
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Table 3. 400 MHz 
1
H NMR spectra of HCl salts in CDCl3. 
Proton TCPr (1c) 2-MeO-PCPr (2c) 3-MeO-PCPr (3c) 4-MeO-PCPr (4c) 3-Me-PCPr (5c) 
H2,6 2.73 d (12.7 Hz, 2Heq) 
2.47–2.32 m (2Hax) 
2.65–2.50 m (2Heq) 
2.45 td (13.0, 3.6 Hz, 2Hax) 
 
2.78 d (12.6 Hz, 2Heq) 
2.35 td (13.0, 3.5 Hz, 2Hax) 
2.79 d (12.5 Hz, 2Heq) 
2.34 td (12.9, 3.5 Hz, 2Hax) 
2.81 d (12.6 Hz, 2Heq) 
2.35 td (13.0, 3.5 Hz, 
2Hax) 
H3,5 1.85–1.74 m (2Heq) 
1.53–1.37 m (2Hax) 
1.93–1.76 m (2Heq) 
1.46–1.19 m (2Hax) 
1.83–1.71 m (2Heq) 
1.34 qt (13.0, 3.5 Hz, 2Hax) 
1.81–1.69 m (2Heq) 
1.29 qt (13.2, 3.4 Hz, 2Hax) 
1.82–1.70 m (2Heq) 
1.29 qt (12.7, 3.5 Hz, 
2Hax) 
 
H4 1.66–1.56 m (1Heq) 
1.53–1.37 m (1Hax) 
1.66–1.57 m (1Heq) 
1.51 qt (12.3, 3.7 Hz, 1Hax) 
1.70–1.53 m (1Heq) 
1.46 qt (12.5, 3.7 Hz, 1Hax) 
1.65–1.53 m (1Heq) 
1.47 qt (12.6, 3.8 Hz, 1Hax) 
1.64–1.54 m (1Heq) 
1.48 qt (12.8, 3.7 Hz, 
1Hax) 
H1’ – – – – – 
H2’ 7.48 dd (3.6, 1.4 Hz) – 7.47 t (2.1 Hz) 7.71 dm (8.9 Hz) 7.66 s 
H3’ 7.10 dd (5.1, 3.5 Hz) 7.01 dd (8.8, 1.2 Hz) – 6.99 dm (8.9 Hz) – 
H4’ 7.39 dd (5.2, 1.2 Hz) 7.45–7.37 m 6.92 ddd (8.0, 2.3, 0.9 Hz) – 7.56 d (8.0 Hz) 
H5’  7.06 td (7.6, 1.2 Hz) 7.36 t (8.0 Hz) 6.99 dm (8.9 Hz) 7.35 t (7.7 Hz) 
H6’ – 7.45–7.37 m 7.32–7.25 m 7.71 dm (8.9 Hz) 7.19 d (7.7 Hz) 
Hα 2.66–2.51 m (CH2) 2.65–2.50 m (CH2) 2.50–2.40 m (CH2) 2.50–2.39 m (CH2) 2.46–2.40 m (CH2) 
Hβ 1.98–1.83 m (CH2) 1.93–1.76 m (CH2) 1.97–1.83  m (CH2) 1.96–1.81 m (CH2) 1.96–1.82 m (CH2) 
Hγ 0.84 t (7.5 Hz, CH3) 0.83 t (7.4 Hz, CH3) 0.80 t (7.4 Hz, CH3) 0.79 t (7.4 Hz, CH3) 0.79 t (7.7 Hz, CH3) 
Hc – 3.98 s (OCH3) 3.91 s (OCH3) 3.84 s (OCH3) 2.43 s (CH3) 
NH
+
 9.58 s (NH2
+
) 9.00 bs (NH2
+
) 9.47 s (NH2
+
) 9.38 s (NH2
+
) 9.44 s (NH2
+
) 
* b = broad; d = doublet; m = multiplet; s = singlet; triplet; q = quartet; quint = quintet; sex = sextet. 
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Table 4.  100 MHz 
13
C NMR spectra of HCl salts in CDCl3. 
Carbon TCMe (1a) 2-MeO-PCMe (2a) 3-MeO-PCMe (3a) 4-MeO-PCMe (4a) 3-Me-PCMe (5a) 
C1 61.95 64.08 63.64 63.26 63.49 
C2,6 34.68 32.42 33.28 33.21 33.16 
C3,5 22.12 22.74 22.03 21.99 22.02 
C4 24.66 25.06 24.96 25.90 25.01 
C1’ 139.71 123.20 136.91 126.68 135.14 
C2’ 128.66 157.42 112.93 129.43 128.56 
C3’ 127.81 111.59 160.48 114.44 139.02 
C4’ 127.03 130.36 115.14 159.68 124.99 
C5’ – 120.69 129.98 114.44 129.00 
C6’ – 130.48 120.09 129.43 129.57 
α 25.97 26.95 26.10 25.03 26.09 
β – – – – – 
γ – – – – – 
Cc – 55.65 55.65 55.24 21.61 
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Table 5.  100 MHz 
13
C NMR spectra of HCl salts in CDCl3. 
Carbon TCE (1b) 2-MeO-PCE (2b) 3-MeO-PCE (3b) 4-MeO-PCE (4b) 3-Me-PCE (5b) 
C1 62.60 64.81 64.30 63.94 64.15 
C2,6 34.93 32.54 33.44 33.39 33.33 
C3,5 22.36 22.76 22.30 22.23 22.29 
C4 24.71 24.92 25.05 25.13 25.09 
C1’ 139.98 123.96 137.01 126.86 135.19 
C2’ 128.88 157.06 113.26 129.72 128.83 
C3’ 127.86 111.94 160.42 114.43 138.99 
C4’ 126.98 130.50 115.01 159.61 125.31 
C5’ – 121.23 129.94 114.43 128.98 
C6’ – 130.37 120.41 129.72 129.47 
α 36.73 37.25 36.79 36.58 36.76 
β 11.95 12.84 12.07 11.98 12.01 
γ – – – – – 
Cc – 55.57 55.72 55.23 21.66 
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Table 6.  100 MHz 13C NMR spectra of HCl salts in CDCl3. 
Carbon TCPr (1c) 2-MeO-PCPr (2c) 3-MeO-PCPr (3c) 4-MeO-PCPr (4c) 3-Me-PCPr (5c) 
C1 62.73 64.84 64.42 64.05 64.26 
C2,6 34.89 32.32 33.21 33.36 33.29 
C3,5 22.40 22.79 22.34 22.22 22.32 
C4 24.71 24.86 25.05 25.12 25.08 
C1’ 139.98 123.92 137.02 126.88 135.20 
C2’ 128.91 156.81 113.23 129.74 128.85 
C3’ 127.85 111.93 160.45 114.41 139.00 
C4’ 126.98 130.57 115.05 159.59 125.33 
C5’ – 121.36 129.92 114.41 128.94 
C6’ – 130.41 120.44 129.74 129.48 
α 43.29 43.64 43.35 43.17 43.31 
β 19.95 20.30 20.07 19.97 20.00 
γ 11.49 11.05 11.45 11.45 11.44 
Cc – 55.53 55.74 55.22 21.67 
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